CSTL
Castle Biosciences, Inc.
NASDAQ · USHealthcareMedical - Diagnostics & Research
$23.89-1.10%
Price as of Jul 20, 2026
CSTL financials
Castle Biosciences, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $344.2M | $332.1M | $219.8M | $137.0M |
| Cost of revenue | $71.0M | $60.2M | $45.0M | $32.0M |
| Gross profit | $273.2M | $271.9M | $174.8M | $105.0M |
| Operating expenses | $316.0M | $263.2M | $242.8M | $177.9M |
| Operating income | -$42.8M | $8.7M | -$68.0M | -$72.9M |
| Net income | -$24.2M | $18.2M | -$57.5M | -$67.1M |
| EBITDA | $11.3M | $38.1M | -$45.0M | -$58.3M |
| Basic EPS | $-0.83 | $0.66 | $-2.14 | $-2.58 |
| Diluted EPS | $-0.83 | $0.62 | $-2.14 | $-2.58 |
| Balance sheet | ||||
| Cash & equivalents | $116.7M | $119.7M | $98.8M | $122.9M |
| Total assets | $578.6M | $531.2M | $453.3M | $447.3M |
| Total liabilities | $107.7M | $75.4M | $62.1M | $48.2M |
| Stockholders’ equity | $470.9M | $455.8M | $391.3M | $399.1M |
| Total debt | $36.9M | $26.3M | $15.3M | $13.4M |
| Net debt | -$79.8M | -$93.4M | -$83.5M | -$109.5M |
| Cash flow | ||||
| Operating cash flow | $64.3M | $64.9M | -$5.6M | -$41.7M |
| Capital expenditure | -$36.0M | -$28.3M | -$13.6M | -$5.6M |
| Free cash flow | $28.3M | $36.5M | -$19.2M | -$47.3M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |